ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Determinants and Machine Learning Prediction of Subtherapeutic Sodium Valproate Concentrations in Epilepsy Management in Xinjiang, China.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectiveValproic acid is a classic antiepileptic drug; however, it is characterized by a narrow therapeutic window, limited safety margin, and marked individual variability. Therapeutic drug monitoring has become a key approach for individualized dosing of valproic acid. Nevertheless, in settings with limited medical resources, routine monitoring of valproic acid concentrations is often not feasible. This study aims to explore the factors influencing valproic acid concentrations and to identify machine learning algorithms with the most accurate classification performance, thereby supporting clinicians in the rational and individualized use of valproic acid in patients with epilepsy.
methodsPatients receiving valproic acid were divided into a subtherapeutic group (< 50 mg/L) and therapeutic range group (50-100 mg/L). Least absolute shrinkage and selection operator (lasso) logistic regression was used to identify factors associated with subtherapeutic group. Multiple machine learning algorithms were also employed to construct binary classification models for predicting whether serum concentrations fall within the therapeutic range.
resultsA total of 186 patients were ultimately included, comprising 110 patients in the therapeutic range group and 76 patients in the subtherapeutic group. Significant differences existed between the two groups in daily dosing frequency, total daily dose, route of administration, and alkaline phosphatase levels (P < 0.05). Lasso logistic regression analysis showed that daily dosage frequency (OR 0.163, P < 0.001) was the only clinically significant independent protective factor for achieving therapeutic blood concentration. The support vector machine (SVM) model achieved high values in the area under the curve (AUC), sensitivity, specificity, and accuracy for both the training and test sets, demonstrating strong generalization ability.
conclusionsIncreasing the daily dosing frequency of valproic acid is associated with a higher likelihood of achieving therapeutic serum concentrations. The results of this study suggest that a binary SVM model can be used to predict the risk of subtherapeutic levels.
Indexed as
Identifiers
42107022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.